- Home
- CLPS vs ALXO Comparison
CLPS vs ALXO Comparison
Compare CLPS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPS
- ALXO
- Stock Information
- Founded
- CLPS 2005
- ALXO 2015
- Country
- CLPS Hong Kong
- ALXO United States
- Employees
- CLPS N/A
- ALXO N/A
- Industry
- CLPS Computer Software: Prepackaged Software
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- CLPS Technology
- ALXO Health Care
- Exchange
- CLPS Nasdaq
- ALXO Nasdaq
- Market Cap
- CLPS 26.9M
- ALXO 24.0M
- IPO Year
- CLPS 2018
- ALXO 2020
- Fundamental
- Price
- CLPS $0.92
- ALXO $0.68
- Analyst Decision
- CLPS
- ALXO Strong Buy
- Analyst Count
- CLPS 0
- ALXO 6
- Target Price
- CLPS N/A
- ALXO $3.30
- AVG Volume (30 Days)
- CLPS 8.1K
- ALXO 575.0K
- Earning Date
- CLPS 03-05-2025
- ALXO 08-12-2025
- Dividend Yield
- CLPS 14.44%
- ALXO N/A
- EPS Growth
- CLPS N/A
- ALXO N/A
- EPS
- CLPS N/A
- ALXO N/A
- Revenue
- CLPS $153,816,045.00
- ALXO N/A
- Revenue This Year
- CLPS N/A
- ALXO N/A
- Revenue Next Year
- CLPS N/A
- ALXO N/A
- P/E Ratio
- CLPS N/A
- ALXO N/A
- Revenue Growth
- CLPS 5.81
- ALXO N/A
- 52 Week Low
- CLPS $0.74
- ALXO $0.40
- 52 Week High
- CLPS $1.70
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- CLPS 45.50
- ALXO 56.17
- Support Level
- CLPS $0.90
- ALXO $0.60
- Resistance Level
- CLPS $0.93
- ALXO $0.64
- Average True Range (ATR)
- CLPS 0.03
- ALXO 0.06
- MACD
- CLPS -0.00
- ALXO 0.00
- Stochastic Oscillator
- CLPS 30.12
- ALXO 52.92
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.